



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: pNL4-3.HSA.R+

Catalog Number: 3419

Lot Number: 020734

Release Category: C

Provided: 1 ml transformed DH5a (glycerol stocks).

Cloning Vector: pUC-19.

Description: Encodes replication competent proviral DNA.
Replication-competent proviral DNA.

Special Characteristics: Murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene to produce this clone. Virus can be produced by transfecting 2×10^6 293 or 293T cells with 20 μ g NL4-3 DNA. Transfections can be performed in a 10 cm² tissue culture dish using standard calcium phosphate protocols. Virus is typically harvested 48 hours post-transfection. Infections should be performed in a total volume of 0.5 ml. The amphotropic pseudotypes generally have much higher infectivity than those bearing HIV-1 env. Cultures infected with HSA viruses can be assayed by FACS analysis with a commercial CD24 antibody (Pharmingen) 2-5 days post-infection.

[Plasmid Map](#)

Recommended Storage: -70°C.

Contributor: Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol* **69**:6705-6711, 1995. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. *Virology* **206**:935-944, 1995.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3.HSA.R+ from Dr. Nathaniel Landau." Also include the references cited above in any publications. Patent pending.

Last Updated May 31, 2016

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.